OS Benefit from TTFields with Gemcitabine/Nab-paclitaxel for Patients with Unresectable Locally Advanced Pancreatic Adenocarcinoma By Ogkologos - August 4, 2025 727 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PANOVA-3 study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR New on NCI’s Websites for November 2024 November 1, 2024 Cancer.Net’s 20th Anniversary: Celebrating Our Mission of Providing Trustworthy Cancer Information May 17, 2022 Rapid, Robust and Durable Antitumour Activity of Pralsetinib in Patients with... August 26, 2022 Nirogacestat May Offer Hope to People with Desmoid Tumors May 1, 2023 Load more HOT NEWS Hormone Therapy Can Put Cancer Cells Into Sleep Mode And Cause... Significant iDFS Benefit with Adding Ribociclib to a Nonsteroidal Aromatase Inhibitor... Foodie Fridays: It’s Cucumber Season! Paralyzed Bride Walks Down Aisle At Her Wedding & Surprises Groom
